Legal & General Group
CAMP icon

Legal & General Group’s CAMP4 Therapeutics CAMP Stock Holding History

Legal & General Group’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-708
Closed -$2.81K – 3436
2025
Q1 		$2.81K Hold
708
– – ﹤0.01% 3334
2024
Q4 		$3.7K Buy
+708
New +$5.82K ﹤0.01% 3361

Other funds holding CAMP

ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Legal & General Group's CAMP Position: Q2 2025 in Review

Legal & General Group sold out of CAMP4 Therapeutics (CAMP) in Q2 2025, closing a stake of 708 shares — an estimated $2.81K sold.

Legal & General Group first reported a position in CAMP in Q4 2024 and held it in 2 quarters. The position peaked at $3.7K in Q4 2024. 29 funds tracked by Wall St. Rank hold CAMP as of Q2 2025.

  • Legal & General Group reported no remaining CAMP4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 708 CAMP4 Therapeutics shares in Q2 2025, an estimated $2.81K.
  • Legal & General Group first reported a position in CAMP4 Therapeutics in Q4 2024 and held it in 2 quarters.
  • Legal & General Group's CAMP4 Therapeutics position peaked at $3.7K in Q4 2024.
  • 29 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.